Can Fite Biopharma Stock Net Income
| CANF Stock | USD 4.29 0.11 2.50% |
Fundamental analysis of Can Fite allows traders to better anticipate movements in Can Fite's stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Can Fite Biopharma Company Net Income Analysis
Can Fite's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Can Fite Net Income | (7.88 M) |
Most of Can Fite's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Can Fite Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Can Fite Biopharma reported net income of (7.88 Million). This is 102.31% lower than that of the Biotechnology sector and 111.25% lower than that of the Health Care industry. The net income for all United States stocks is 101.38% higher than that of the company.
Can Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Can Fite's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Can Fite could also be used in its relative valuation, which is a method of valuing Can Fite by comparing valuation metrics of similar companies.Can Fite is currently under evaluation in net income category among its peers.
Can Fundamentals
| Return On Equity | -2.64 | ||||
| Return On Asset | -0.82 | ||||
| Operating Margin | (24.25) % | ||||
| Current Valuation | 48.19 B | ||||
| Shares Outstanding | 17.07 M | ||||
| Shares Owned By Institutions | 5.53 % | ||||
| Number Of Shares Shorted | 51.4 K | ||||
| Price To Earning | (3.41) X | ||||
| Price To Book | 17.95 X | ||||
| Price To Sales | 1,357 X | ||||
| Revenue | 674 K | ||||
| Gross Profit | 560 K | ||||
| EBITDA | (8.12 M) | ||||
| Net Income | (7.88 M) | ||||
| Cash And Equivalents | 12.77 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 104 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.78 X | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (7.64 M) | ||||
| Short Ratio | 0.19 X | ||||
| Target Price | 3.5 | ||||
| Beta | 0.042 | ||||
| Market Capitalization | 15.24 M | ||||
| Total Asset | 9.12 M | ||||
| Retained Earnings | (166.36 M) | ||||
| Working Capital | 6.93 M | ||||
| Current Asset | 39.51 M | ||||
| Current Liabilities | 5.77 M | ||||
| Net Asset | 9.12 M |
About Can Fite Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Can Fite Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Can Fite using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Can Fite Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:Check out Can Fite Piotroski F Score and Can Fite Altman Z Score analysis. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.